Charles River Laboratories International, Inc. and Deciphex Limited Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
April 11, 2024 at 01:00 pm
Share
Charles River Laboratories International, Inc. announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI) decision support tool developed in collaboration with Deciphex Limited, an innovator in pathology AI. By combining Deciphex?s unique digital pathology solutions with Charles River?s robust non-clinical pathology programs, clients of both organizations will have access to the technology-driven capabilities to accelerate primary evaluation and peer review in toxicologic pathology assessment, enhancing decision-making in drug discovery and safety assessment. In experimental and toxicologic pathology in particular, traditional light microscopic pathology methods can fall short of maintaining consistency and efficiency in analyzing histopathology data.
By augmenting evaluations with decision support technology, toxicologic pathologists have access to simple, visual tools to facilitate efficiency, consistency, and accuracy in their work. Developed through a research collaboration between Charles River and Deciphex, Patholytix Foresight incorporates organ-based lesion classifiers created from an extensive data warehouse. Built on Patholytix 4.0, Deciphex's flagship non-clinical workflow, the tool integrates these AI classifiers with Whole Slide Images (WSI) to enhance and accelerate a pathologist?s decision-making by streamlining workflows for identifying critical features in specific tissues.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows:
- discovery and safety assessment services (63.4%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides;
- development and sale of research models and related services (19.2%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ;
- development of solutions used in drug manufacturing processes (17.5%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies.
Net sales break down by source of income between sales of services (83.3%) and sales of products (16.7%).
Net sales are distributed geographically as follows: the United States (56.8%), Europe (26%), Canada (11.8%), Asia/Pacific (4.9%) and other (0.4%).
Charles River Laboratories International, Inc. and Deciphex Limited Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology